Kyverna Therapeutics, INC 10-Q quarterly reports

Kyverna Therapeutics announced a First Amendment to its Loan and Security Agreement, extending loan availability and outlining new covenants, while also providing updates on its CAR T therapies for autoimmune diseases.

Kyverna Therapeutics reported a decrease in R&D expenses for Q1 2026, alongside progress in its clinical trials for autoimmune diseases.

Kyverna Therapeutics reports increased net losses for Q3 and nine months ended September 30, 2025, while advancing its lead cell therapy candidate KYV-101 in late-stage clinical trials for autoimmune diseases and securing new financing.

Kyverna Therapeutics reported increased net losses in Q2 2025 driven by higher R&D expenses, while making significant clinical progress with its lead cell therapy candidate KYV-101 for autoimmune diseases.

Kyverna Therapeutics reports a net loss of $44.6 million for Q1 2025, focusing on advancing its lead product candidate, KYV-101, through clinical trials.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company, announced its third quarter 2024 financial results, highlighting increased operating expenses due to ongoing clinical trials and research and development activities.

Kyverna Therapeutics reports a net loss of $28.8 million for the second quarter of 2024, alongside significant increases in research and development expenses.

Kyverna Therapeutics reports a net loss of $26.7 million for the first quarter of 2024, alongside significant increases in research and development expenses and a successful IPO that generated $336.2 million in net proceeds.